CLCA1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06205(CLCA1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CLCA1 (Calcium-Activated Chloride Channel Accessory 1) is a member of the CLCA protein family, initially identified as a regulator of calcium-sensitive chloride conductance in epithelial cells. Although its precise mechanistic role remains debated, CLCA1 is recognized for its involvement in mucus production, airway remodeling, and inflammatory responses. It is expressed predominantly in secretory epithelial cells of the respiratory, intestinal, and reproductive tracts. Structurally, CLCA1 undergoes self-cleavage to generate a secreted glycoprotein and a membrane-associated fragment, suggesting dual roles in extracellular signaling and ion channel modulation.

Research links CLCA1 to chronic inflammatory diseases, particularly asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). In asthma, CLCA1 overexpression correlates with mucus hypersecretion and Th2-driven inflammation, interacting with pathways like IL-13/STAT6. Conversely, its role in IBD appears context-dependent, with studies reporting both pro- and anti-inflammatory effects.

CLCA1 antibodies are tools to detect and quantify CLCA1 expression in tissues or biofluids, aiding research on disease mechanisms. They are used in techniques like immunohistochemistry, Western blotting, and ELISA. Some antibodies target specific domains (e.g., secreted vs. membrane-bound forms) to dissect functional contributions. Commercial antibodies vary in specificity, requiring validation via knockout controls. Emerging clinical interest explores CLCA1 as a biomarker for disease progression or therapeutic targeting, though its therapeutic potential remains under investigation. Challenges include clarifying its molecular interactions and reconciling disparate findings across disease models.